ArticleJournal for immunotherapy of cancer2024

Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy.

Yanyang Nan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.